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Chronic lung diseases and chronic obstructive 
pulmonary disease: a need for innovation
Chronic lung diseases (CLDs), including chronic obstruc-
tive pulmonary disease (COPD), asthma, lung cancer, 
neonatal chronic lung disease and pulmonary fi brosis, 
are the leading diseases worldwide with regard to mor-
tality, prevalence and socioeconomic burden [1,2]. Th e 
devastating impact of these diseases is largely due to 
increased environmental eff ects on lung health in recent 
years (for example, air pollution, allergens, and cigarette 
smoke or related particles), limited understanding of 
their mechanisms of pathogenesis, and consequently, 
insuffi  cient therapeutic options. Importantly, COPD is 
the only leading cause of death with increasing incidence 
among the top diseases: by 2020, more than 6  million 
deaths every year are projected to be due to COPD [2].
COPD is defi ned as ‘a decreased airfl ow that is not fully 
reversible’ and is classically diagnosed by lung function 
testing (FEV1, forced expiratory volume in one second). 
Pathologically, COPD is characterized by airway infl am-
mation, loss of functional alveolar tissue, irreversible 
airfl ow obstruction and loss of lung function [3,4]. It has 
two main pathological features: small airway disease 
(SAD; which includes airway infl ammation with increased 
mucous production, activation of immune cells, airway 
wall remodeling and peribronchiolar fi brosis) and 
emphy sema (defi ned as the destruction of the distal 
alveolar architecture due to distal airspace enlargement). 
Ultimately, both features can lead to a loss of functional 
alveolar epithelium and impaired lung function, with an 
apparent inability of the lung to self-repair.
It has long been known that a decline in lung function 
does not accurately correlate with the degree of emphy-
sema or SAD. It has therefore been a major challenge to 
defi nitively phenotype COPD patients with regard to their 
underlying dominant pathological process (that is, 
emphysema or SAD), and this has hampered clinical study 
design and drug discovery. Until recently, approaches for 
the accurate correlation of gene expression signatures with 
histological subtypes of COPD were not available, and this 
has prevented the molecular characterization of cell 
populations involved in dominant pathogenic processes at 
diff erent stages of COPD/emphysema. Th is is in striking 
contrast to the extensive profi ling of idio pathic pulmonary 
fi brosis (IPF), which has resulted in a clear gene expression 
signature in the lungs and blood of individuals with IPF, 
accelerating biomarker identifi cation and disease 
stratifi cation for this disease in recent years [5].
De nition of a strong disease signature
A recent study by Campbell et al. published in Genome 
Medicine now appears to overcome these challenges in 
COPD [6]. Th e study is remarkable for the following 
reasons: (1)  gene signatures in diff erent grades of 
emphysema were derived from regions of quantitatively 
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assessed pathology (by micro-computed tomography and 
stereology); (2)  these signatures were extensively com-
pared with available COPD datasets published by diff er-
ent groups; (3)  these validated signatures were then 
queried using the Connectivity Map (CMap) [7,8] for 
compounds that might be capable of reversing the 
emphysematous phenotype; and (4)  one identifi ed 
compound (the tripeptide GHK) was then tested in vitro 
for proof-of-principle (Figure 1).
In a joint venture by several leading COPD groups, a 
comprehensive approach was then used to assess gene 
expression patterns in lung regions of COPD specimens 
with defi ned severities of emphysema [6]. Th e venture 
included groups with outstanding expertise in micro- 
and macro-imaging of the lung, gene expression analysis, 
clinical phenotyping, and most importantly, bioinfor-
matics. Th e authors made use of a recently published 
novel method to assess regional severity of emphysema 
by determining the mean linear intercept between alveolar 
walls using micro-computed tomography [4]. Th ey 
identifi ed a set of 127 diff erentially regulated genes that 
were signifi cantly associated with the degree of emphy-
sema in the lung. Importantly, this signature was further 
validated using gene expression data from other cross-
sectional studies of COPD. Th is signature of 127 genes 
was signifi cantly enriched among COPD-regulated genes 
in four out of fi ve previously published data sets, validat-
ing this set as a strong signature for lung emphysema.
Importantly, enrichment analysis of gene functions 
revealed an over-representation of genes involved in B-
cell receptor signaling and reduced expression of genes 
involved in transforming growth factor (TGF)-β signal-
ing. Indeed, an increasing number of CD79A-positive B 
cells correlated with the severity of emphysema, as shown 
by immunohistochemical analysis. Using an elegant 
bioinformatics approach, the authors further validated 
these gene sets by comparing them with a defi ned TGF-β 
activation signature, using seven publicly available gene 
expression studies on TGF-β-induced gene expression. 
Interestingly, both the induction of B-cell receptor 
signaling and downregulation of TGF-β activation were 
not fully appreciated in previous COPD profi ling studies. 
Th us, strong and validated disease signatures depend on 
the stringency of data analysis and comparison with 
apparently unrelated, publicly available data sets from 
other studies.
Unbiased identi cation of new drugs
Another strength of the study by Campbell and 
colleagues [6] lies in the use of the enriched emphysema 
gene expression signature for an unbiased drug screening 
approach by in silico connectivity mapping. CMap exploits 
the transcriptome as a ‘universal language’ describing 
cellular responses [7,8] to distinct drugs to connect drug 
discovery, biology and disease phenotypes. Classically, to 
exploit CMap, a disease phenotype, represented by a 
strong gene expression signature (in this case emphy-
sema), is compared with gene expression profi les of cells 
that have been treated with distinct drugs (here GHK) for 
various exposure times. While the initial CMap reference 
catalogue comprised gene expression profi les of 164 
drugs, the current catalogue contains 1,309 Food and 
Drug Administration (FDA)-approved small molecules 
that have been evaluated in fi ve cancer cell lines [8]. 
CMap can thus be used as an unbiased in silico screening 
approach to identify drugs that have either positive or 
negative connectivity scores, implicating these drugs 
either as potential inducers of disease phenotypes or 
therapeutics thereof.
Campbell and co-workers used their enriched 
emphysema signature and screened for compounds that 
demonstrated connectivity with regard to gene expres-
sion changes observed in emphysema. Connectivity 
analysis was performed with high stringency by double 
fi tting of the two gene expression signatures, that is, 
induced with severity of emphysema and deactivated 
TGF-β signaling. Th ey identifi ed the tripeptide GHK, a 
natural tripeptide involved in wound healing, which 
showed inverse connectivity. Importantly, in experi men tal 
studies using GHK, it partially reversed emphysema-
associated phenotypes in fi broblasts from COPD patients.
Future directions
It will now be of utmost interest and importance to see 
whether further animal experiments will confi rm that 
Figure 1. A template for new drug discovery. The general strategy 
used by Campbell et al. [6] is outlined on the left. The detailed 
fi ndings of each step from the paper are depicted on the right.
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GHK is indeed able to revert disease in vivo, using 
relevant animal models of emphysema or COPD. If this is 
shown to be the case, clinical studies will then surely 
investigate whether GHK has clinical potential for 
individuals with COPD with a dominant emphysematous 
phenotype. It will be interesting to see whether such a 
comparative bioinformatics approach will generate new 
and/or overlapping gene expression signatures in lung, 
blood or bronchoalveolar lavage samples not only in 
COPD, but also in other heterogeneous CLD, such as 
asthma or chronic neonatal lung disease.
Since the release of CMap, several studies have shown 
the feasibility of this drug-screening approach for the 
identification of new therapeutics, drug repurposing, and 
the prediction of off-target or side effects, as reviewed by 
Qu and Rajpal [8]. Recently, Wang and colleagues [9] 
applied a similar in silico approach to screen for candi-
date therapeutic compounds for lung adenocarci noma. 
The CMap approach also offers the possibility of predict-
ing synergies of drug combinations. In the future, the use 
of CMap might also add to our understanding of disease 
pathogenesis by connecting gene expression profiles of 
drugs that specifically inhibit single pathways with trans-
criptional profiles of disease phenotypes.
The use of gene expression profiling in histologically 
quantified tissue specimens with CMap querying reveals 
an exciting new approach to perform knowledge-based 
drug screening. Biomedical research has classically 
involved the tedious mechanistic understanding of single 
molecular targets and their interactions as a starting 
point for lead compound identification and subsequent 
optimization, but future research might move towards a 
more empirical analysis of gene expression signatures in 
combination with drug signatures.
In summary, the approach described herein (Figure 1) 
might facilitate lead compound identification and re-
purposing of drugs. Drug discovery is currently estimated 
to take approximately 15 years, with 90% of drugs failing 
to move beyond early clinical testing stages [10]. 
Therefore, such an approach is expected to save precious 
time and money, and ultimately might have the potential 
to decrease disease burden more effectively.
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